European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis

Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the Eur... Biopharmaceuticals, Regulatory Eli Lilly, Incyte , Olumiant, baricitinib, rheumatoid arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news